- News Home
17 April 2014 12:48 pm ,
Vol. 344 ,
Officials last week revealed that the U.S. contribution to ITER could cost $3.9 billion by 2034—roughly four times the...
An experimental hepatitis B drug that looked safe in animal trials tragically killed five of 15 patients in 1993. Now,...
Using the two high-quality genomes that exist for Neandertals and Denisovans, researchers find clues to gene activity...
A new report from the Intergovernmental Panel on Climate Change (IPCC) concludes that humanity has done little to slow...
Astronomers have discovered an Earth-sized planet in the habitable zone of a red dwarf—a star cooler than the sun—500...
Three years ago, Jennifer Francis of Rutgers University proposed that a warming Arctic was altering the behavior of the...
- 17 April 2014 12:48 pm , Vol. 344 , #6181
- About Us
U.K. Cancer Funders May Unite
17 January 2001 7:00 pm
A giant funding agency akin to the U.S. National Cancer Institute may be in store for British cancer research. Trustees of the two largest private cancer charities in Britain--the Imperial Cancer Research Fund (ICRF) and the Cancer Research Campaign (CRC)--met yesterday to discuss future collaboration plans, including a full merger.
The organizations stress that the talks are at an "exploratory" stage, and that several levels of collaboration are being considered. A full merger would improve efficiency, says ICRF director general Paul Nurse: "Facilities are very expensive, and the best solution may be to pool our resources." In addition, one national organization would be better able to train young researchers and would give cancer research a stronger voice, Nurse says.
Currently, there's little overlap in what the charities do: The ICRF, with an annual research expenditure of $96 million, conducts research at its main institute in London and at its own clinical research units throughout the U.K., while the CRC acts mainly as a granting agency that spends about $94 million a year on research projects across the country.
Scientists welcomed the possible merger. "There has always been a balance between competition and duplication, and a major effect of any merger will be increased coordination," says David Lane, head of a research unit into the molecular basis of human cancer at the University of Dundee, who gets funding from the CRC. But Lane worries that a combined charity may not rake in as many donations as two separate ones.
A preliminary report about the road ahead will be presented to the organizations' councils later this month. A final decision is not expected until later this year.